Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-09-12
1997-06-10
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 41, 536 172, 536 179, 536 187, 536 552, 536 553, A61K 3170, C07H 1510
Patent
active
056375697
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to analogs of gangliosides, a method for preparation of such compounds, use of such compounds to induce immune response and as inhibitors of adhesion of bacteria and viruses, as well as in the production of antibodies against the compounds, antibodies against the compounds as well as use of the antibodies in therapy or diagnosis.
BACKGROUND OF THE INVENTION
Gangliosides, i.e. sialic acid-containing glycosphingolipids, are well-known components of the mammalian cell surfaces. Furthermore, gangliosides have been found to occur in equilibrium with the corresponding lactones. Thus, GM.sub.3 - and GD.sub.3 -ganglioside [NeuAc.alpha.(2-3)Gal.beta.(1-4)Glc.beta.O-Ceramide and NeuAc.alpha.(2-8)NeuAc.alpha.(2-3)Gal.beta.(1-4)Glc.beta.O-Ceramide] have been demonstrated to form lactones where the sialic acid-derived carbonyl group enters into lactone formation with various hydroxyl groups of the NeuAc and Gal residues. Furthermore, it has been shown that such lactones exist in vivo, e.g. in brain tissue and in the membranes of tumour cells, and are not just artifacts of the isolation procedures (Gross, S. K.; Williams, M. A.; McCluer, R. H. J. Neurochem. 1980, 34, 1351-1361). It has also been shown that GM.sub.3 -lactone is much more immunogenic than is the open form of GM.sub.3 -ganglioside (Nores, G. A.; Dohi, T.; Taniguchi, M.; Hakomori, S.-I. J. Immun. 1987, 139, 3171-3176).
It has also been suggested that GM.sub.3 -lactone is a highly rigid structure with the lactone ring in a chair-like conformation (see scheme 1 below) which would mean that its ability to serve as a recognition site or membrane antigen could be enhanced, compared to its parent structure, which is flexible (Yu, R. K.; Koerner, T. A. W.; Ando, S.; Yohe, H. C.; Prestegaard, J. H. J. Biochem. 1985, 98, 1367-1373). Furthermore, the lactone of GM.sub.3 -ganglioside ("GM.sub.3 -lactone") has been suggested to be a tumour-associated antigen on the cells of an experimental mouse melanoma (Nores, G. et al. cited above). In a comparative immunization with GM.sub.3 -ganglioside and the corresponding lactone, the same authors showed that the lactone is the stronger immunogen, and it was suggested that this compound could be the real immunogen despite being a minor membrane component. Furthermore, the activity of a monoclonal anti-melanoma antibody (M2590) with various cells and liposomes was shown to depend in a threshold, all-or-none, fashion on the concentration of GM.sub.3 -ganglioside in the cell membrane or liposome. Also, the antibody was found to cross-react with GM.sub.3 -lactone.
The ganglioside lactones are unstable at neutral pH while acidic conditions favour the lactone in the equilibrium between GM.sub.3 -ganglioside and GM.sub.3 -lactone. However, since GM.sub.3 -ganglioside is itself acidic since it is an acid-containing glycolipid, the ganglioside might possibly induce its own lactonization when the concentration is sufficiently high in a cell membrane or liposome. This might help to explain the threshold effect described above and might have similar implications for other sialic acid-containing saccharides.
Thus, although a ganglioside lactone has been shown to be far more immunogenic than the open-form ganglioside, the low equilibrium concentration of the lactone at pH-values close to neutral will probably render the lactone to be a rather inefficient immunogen. Thus, it is clear that it would be desirable to have a non-labile immunogenic compound resembling the lactone form of a ganglioside and which is capable of raising antibodies (and other entities of the immune system) capable of at least partial cross-reaction with the ganglioside lactone.
SUMMARY OF THE INVENTION
In one aspect, the present invention relates to ganglioside analogs which spatially closely resemble gangliosides and which are therefore contemplated to be able to induce the production of antibodies that will cross-react with the corresponding ganglioside and in turn elicit an immune response directed against t
REFERENCES:
Nores et al., Density-Dependent Recognition of Cell Surface GM.sub.3 by a Certain Anti-Melanoma Anti-Melanoma Antibody, and GM.sub.3 Lactone as a Possible Immunogen; Requirements for Tumor-Associated Antigen and Immunogen, The Journal of Immunology, vol. 139, No. 9, pgs. 3171-3176, Nov. 1, 1987.
Ray et al., Synthesis nad conformational Analysis of GM.sub.3 Lactam, a Hydrolytically Stable Analogue of GM.sub.3 Ganglioside Lactone, J. AM. Chem. Soc., vol. 114, pp. 2256-2257, 1992.
Magnusson Hans G.
Ray Asim K.
Cooper Iver P.
Peselev Elli
Symbicom Aktiebolag
LandOfFree
Ganglioside analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ganglioside analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ganglioside analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-764668